Transplant center directory

Johns Hopkins is a core center of the BMT clinical trials network; COG approved. Current studies are looking at ways to facilitate graft tolerance to reduce the risk of GVHD and reduce graft rejection in patients with mismatched donors, as well as investigating safer ways to transplant non-malignant diseases. Some patients with fully matched donors do not require immune suppression beyond four days after transplantation.

This center has been performing allogeneic transplants since 1969 and has been an NMDP/Be The Match transplant center since October 1997.

This center's actual 1-year survival results are above the expected rate for this center.

The survival information we have for this center includes ONLY:

1. Patients who had their FIRST ALLOGENEIC transplant (cells from a related or unrelated donor/cord blood) during 2019, 2020, 2021, and
2. Who had their transplant at a U.S. transplant center, and
3. Who had follow-up information provided by the transplant center for analysis

For this center, we have survival information for 649 patients.

The actual 1-year survival of these patients is 81.8%.

Compared to similar patients transplanted at all centers in the U.S., we expect that the 1-year survival for patients at this center to be in a range between 75.2% and 81.3%.

For help with understanding these statistics, please see Understanding Transplant Outcomes.

For overall survival for all patients transplanted with a specific disease, please see U.S. Patient Survival report at bloodcell.transplant.hrsa.gov.

All diseases

Number of transplants by age reported from January 1, 2021 to December 31st, 2022 (includes marrow, PBSC and cord blood)

Treatments may be similar for diseases within a group. It might be helpful to look at centers that have done transplants for a specific disease and centers that have done transplants for any corresponding broad disease categories.